1. Home
  2. ACAD vs MTN Comparison

ACAD vs MTN Comparison

Compare ACAD & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Vail Resorts Inc.

MTN

Vail Resorts Inc.

N/A

Current Price

$151.60

Market Cap

5.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
MTN
Founded
1993
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Services-Misc. Amusement & Recreation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.2B
IPO Year
2000
1996

Fundamental Metrics

Financial Performance
Metric
ACAD
MTN
Price
$17.18
$151.60
Analyst Decision
Buy
Hold
Analyst Count
20
15
Target Price
$30.21
★ $148.36
AVG Volume (30 Days)
★ 2.4M
450.9K
Earning Date
11-04-2026
12-09-2026
Dividend Yield
N/A
★ 5.84%
EPS Growth
★ 69.12
N/A
EPS
0.51
★ 4.12
Revenue
$726,437,000.00
★ $2,838,204,000.00
Revenue This Year
$19.55
$7.02
Revenue Next Year
$13.34
$3.71
P/E Ratio
★ $34.47
$36.92
Revenue Growth
★ 40.45
N/A
52 Week Low
$15.86
$118.51
52 Week High
$30.96
$163.99

Technical Indicators

Market Signals
Indicator
ACAD
MTN
Relative Strength Index (RSI) 34.82 49.06
Support Level $15.86 $142.17
Resistance Level $22.71 $154.65
Average True Range (ATR) 1.20 4.60
MACD -0.11 -0.84
Stochastic Oscillator 18.38 12.79

Price Performance

Historical Comparison
ACAD
MTN

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About MTN Vail Resorts Inc.

Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.

Share on Social Networks: